This study is for people with muscle-invasive bladder cancer (MIBC), which means the cancer has spread into the muscle of the bladder. It compares two treatments: a new method using a device called TAR-200 with a drug called cetrelimab against the usual treatment of chemoradiotherapy (using chemicals and radiation to kill cancer cells). The goal is to see which treatment helps people live longer without needing bladder removal surgery.
- This study is only for those who can't or choose not to have bladder removal surgery.
- Participants must pass certain health tests and have no other major cancer or severe bladder damage.
- It includes regular health checks and treatment monitoring.
Before joining, discuss with your doctor if you meet the health criteria, and understand the potential risks and benefits of participating. You'll receive treatments and will be monitored to compare how well each treatment works in keeping the bladder cancer-free.
How understandable was the trial content above?
Hard to understand
Easy to understand